Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Regeneron Pharmaceuticals Inc.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bristol-Myers Squibb (BMY – Research Report) and R...

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Regeneron (REGN)

Evercore ISI analyst Cory Kasimov maintained a Buy rating on Regeneron yesterday and set a price target of $875.00. The company’s shares closed yes...

Evercore ISI Keeps Their Buy Rating on Regeneron (REGN)

In a report released today, Louise Chen from Scotiabank maintained a Hold rating on Regeneron, with a price target of $770.00. According to TipRank...

Scotiabank Reaffirms Their Hold Rating on Regeneron (REGN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Regeneron (REGN – Research Report), Korro Bio (KRRO – Research Re...

Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Korro Bio (KRRO) and AstraZeneca (AZN)

Regeneron Pharmaceuticals (($REGN)) has held its Q4 earnings call. Read on for the main highlights of the call. Regeneron Earnings Call Strikes Con...

Regeneron’s Earnings Call: Growth Engines and Rising Costs

Citi analyst Geoff Meacham maintained a Buy rating on Regeneron today and set a price target of $900.00. Meacham covers the Healthcare sector, focu...

Citi Remains a Buy on Regeneron (REGN)

U.S. stocks finished the week mixed as gains in technology shares helped offset weakness in financial stocks and rising rate pressure. The Dow Jone...

The Week That Was, The Week Ahead: Macro and Markets, Jan. 25

Analysts fell to the sidelines weighing in on Becton Dickinson (BDX – Research Report) and Regeneron (REGN – Research Report) with neutral ratings,...

Analysts’ Top Healthcare Picks: Becton Dickinson (BDX), Regeneron (REGN)

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron’s latest clinical update centers on a Phase 1 tria...

Regeneron Explores New Intralesional Use for Libtayo in Skin Cancer: What Investors Should Know

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Regeneron (REGN – Research Report) and Ocugen (OCGN ...

Analysts’ Top Healthcare Picks: Regeneron (REGN), Ocugen (OCGN)

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Study Overview Regeneron Pharmaceuticals is running a Phase ...

Regeneron Advances Early-Stage Eye Drug Pozelimab in Geographic Atrophy Trial

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Regeneron, with a price target of $885.00. Tewari covers the Hea...

Jefferies Reaffirms Their Buy Rating on Regeneron (REGN)

In a report released yesterday, David Risinger from Leerink Partners reiterated a Buy rating on Regeneron. The company’s shares closed yesterday at...

Leerink Partners Remains a Buy on Regeneron (REGN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Avita Medical (RCEL – Research Report), OrthoPediatrics (KIDS – R...

Analysts Conflicted on These Healthcare Names: Avita Medical (RCEL), OrthoPediatrics (KIDS) and Regeneron (REGN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nuvation Bio (NUVB – Research Report) and Regenero...

Analysts Offer Insights on Healthcare Companies: Nuvation Bio (NUVB) and Regeneron (REGN)

Scotiabank analyst Louise Chen maintained a Hold rating on Regeneron today and set a price target of $770.00. Chen covers the Healthcare sector, fo...

Scotiabank Remains a Hold on Regeneron (REGN)

Exchange-traded funds (ETFs) offer a huge—and often confusing—number of choices. TipRanks’ ETF AI Analyst narrows it down to three ETFs with Outper...

3 Best ETFs to Invest In, According to AI Analyst, 1/7/2026

Regeneron Pharmaceuticals ($REGN), Sanofi SA ($SNY) announced an update on their ongoing clinical study. Study Overview: Sanofi and Regeneron have ...

Current Quarter	$7.14	Next Quarter	$8.97
Current Year	$35.09	Next Year	$41.64
QoQ Growth	+25.6%	YoY Growth	+18.7%
3Y EPS CAGR	-18.8%	Target Price	$835.42
Consensus	Buy	Upside	+10.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	REGN	$755.02	+1.83%	693.00K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	REGN	$755.02	+1.8%	693.00K
3
4
5
6

REGN

REGN

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Regeneron Pharmaceuticals Inc. Data in Excel

Get Regeneron Pharmaceuticals Inc. Data in Excel